Exploring the complexity of xylitol production in the fungal cell factory Aspergillus niger

IF 3.4 3区生物学 Q2 BIOTECHNOLOGY & APPLIED MICROBIOLOGY

Enzyme and Microbial Technology Pub Date : 2024-11-23 DOI:10.1016/j.enzmictec.2024.110550

Astrid Müller , Jiali Meng , Robin Kuijpers , Miia R. Mäkelä , Ronald P. de Vries

引用次数: 0

Abstract

Production of xylitol from agricultural by-products offers a promising approach for the circular bioeconomy. This study investigates the roles of transcription factors XlnR and CreA in xylitol production from wheat bran in Aspergillus niger by generating strains with a constitutively active XlnR (XlnR_c, V756F mutation) and/or deletion of creA, in a previously generated xylitol-producing strain. The XlnR_c mutation increased the initial rate of xylitol production but lowered the overall accumulation. Deletion of creA in this strain significantly improved both the onset and rate of xylitol production, indicating an inhibitory role of CreA in the PCP. These results demonstrate the complexity of metabolic engineering to generate fungal cell factories for valuable biochemicals, such as xylitol, as not only metabolic but also multiple gene regulation aspects need to be considered.

查看原文本刊更多论文

探索真菌细胞工厂黑曲霉生产木糖醇的复杂性

利用农副产品生产木糖醇为循环生物经济提供了一种前景广阔的方法。本研究通过在先前产生的木糖醇生产菌株中产生具有组成型活性 XlnR（XlnRc，V756F 突变）和/或缺失 creA 的菌株，研究了转录因子 XlnR 和 CreA 在黑曲霉利用麦麸生产木糖醇过程中的作用。XlnRc 突变提高了木糖醇的初始生产率，但降低了总体积累。在该菌株中缺失 CreA 能显著提高木糖醇生产的起始率和速率，这表明 CreA 在 PCP 中起抑制作用。这些结果表明了代谢工程的复杂性，即不仅需要考虑代谢方面，还需要考虑多种基因调控方面，才能生成木糖醇等有价值生化物质的真菌细胞工厂。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Enzyme and Microbial Technology 生物-生物工程与应用微生物

CiteScore

7.60

自引率

5.90%

发文量

142

审稿时长

38 days

期刊介绍： Enzyme and Microbial Technology is an international, peer-reviewed journal publishing original research and reviews, of biotechnological significance and novelty, on basic and applied aspects of the science and technology of processes involving the use of enzymes, micro-organisms, animal cells and plant cells. We especially encourage submissions on: Biocatalysis and the use of Directed Evolution in Synthetic Biology and Biotechnology Biotechnological Production of New Bioactive Molecules, Biomaterials, Biopharmaceuticals, and Biofuels New Imaging Techniques and Biosensors, especially as applicable to Healthcare and Systems Biology New Biotechnological Approaches in Genomics, Proteomics and Metabolomics Metabolic Engineering, Biomolecular Engineering and Nanobiotechnology Manuscripts which report isolation, purification, immobilization or utilization of organisms or enzymes which are already well-described in the literature are not suitable for publication in EMT, unless their primary purpose is to report significant new findings or approaches which are of broad biotechnological importance. Similarly, manuscripts which report optimization studies on well-established processes are inappropriate. EMT does not accept papers dealing with mathematical modeling unless they report significant, new experimental data.